Quiz 2 Flashcards
what happens with catalysis with multiple substrates
reactants brought together and properly oriented so they can react
glucose and glucokinase are an example of
the induced fit model for enzymes/substrates
what does glucokinase do
phosphorlyate glucose
when is glucokinase “open”
when no glucose is bound. active in closed state with bound glucose
what [S] is low, what is Vo proportional to
[S] – FIRST ORDER KINETICS
When [S] is high, what is Vo proportional to
equal to Vmax — 0 ORDER KINETICS
what does the rate depend on
the concentration of the substRATE
What does Km represent
the concentration of the substrate where Vo is 50% of Vmax
competitive inhibitor
binds at the same site
Km is increased but Vmax is the same, can reverse the effect by increasing the amount of substrate so that it takes up almost all the receptors on the enzyme
non-competitive inhibitors
doesn’t bind to same spot but makes enzyme less effective.
Km is the same, Vmax is decreased
uncompetitive inhibitor
binds ONLY when substrate is bound because ES complex creates a binding site
-Km AND Vmax are reduced
irreversible inhibitor
bind very strongly or produce covalent modification. Decreased Km but no change on Vmax – like NON competitive
Effector
binds non covalently to subunit of regulatory enzyme. Change in affinity or alters enzymatic activity in a positive or negative way
homotropic effector
substrate itself is the effector. THINK: Hemoglobin! Occupation of first site alters affinity of remaining
Heterotropic effector
substrate is not the effector
what kind of curve does a + cooperativity give
sigmoidal
positive heterotropic effector
binding at the regulatory unit of the enzyme causes conformational shift at the catalytic subunit. NOT COVALENT BINDING.
negative heterotropic effector
feedback inhibition – regulated enzyme typically catalyzes a rate limiting step `
what happens in calcium calmodulin path
Calcium binds to calmodulin cooperatively - with all 4 sites goes from “closed” to “open” and THIS is what binds to CAMKII
what happens when calmodulin binds CAMKII
conformational change which relieves auto-inhibition. CAMKII autophosphorylates so retains activity even after Ca returns to baseline.
What turns off calcium/calmodulin/CAMKII pathway
protein phosphatase which dephosphorylates CAMKII
zymogen
enzyme liberated by proteolysis of inactive precursor
where is trypsinogen released
by the pancreas into the duodenum
what cleaves trypsinogen to trypsin
enteropeptidase
cofactor
additional molecule that helps perform catalysis
metal ion or organic molecule which is usually referred to as coenzyme
apoenzyme vs holoenzyme
holoenzyme is protein + cofactor, apoenzyme is protein alone
isoenzyme
enzyme that catalyzes the same reaction
hexokinase
4 isozymes that phosphorylate simple sugars
glucokinase
hexokinase IV - this is the hexokinase in the liver. MUCH higher Km for glucose than others. Converts XS glucose to glycogen for storage
what is the advantage of the high Km of glucokinase for glucose
when glucose is scare, available glucose will be used by hexokinases in other tissues
Kcat
number of operations a single molecule of an enzyme can perform per second
specificity constant
how efficient enzyme is when free binding sites are available
what does a large specificity constant mean
rxn can proceed at high rate even if substrate concentration is low or enzyme is not highly expressed
how large can a specificity constant be and why
largest is 10^8 or 10^9 because limited by diffusion rates - enzymes that are at this rate are called “catalytically perfect”
what does heme effect
ALA synthase 7 steps earlier in heme synthetic pathway.
ALA is an allosteric enzyme whose activity is under control of an effector (heme).
what do we call inhibitors in pharmacodynamics
antagonists
what is the substrate in pharmacodynamics
drugs!
possible drug receptors
enzymes, channels, G protein coupled receptors
what gets measured with respect to drugs
amount of drug bound to receptor.. NOT rate of reaction
Vmax in pharmacodynamics referred to as
Bmax (max number binding sites)
agonist
drug with intrinsic effect on its target. EXCLUDES drugs that produce their effect by preventing some other ligand from binding because this isn’t intrinsic
EC50
on effect curve, concentration of drug that produces 50% of maximum effect of drug
Emax
on effect curve, area where max effect is produced
instrinsic efficacy
effect per molecule of agonist binding to its receptor
what happens when a signaling pathway is fully activated
this only happens with FULL agonists – even if we add more receptors, can’t produce larger effect!